ProQR Therapeutics BV Total Liabilities
ProQR Therapeutics BV total liabilities. Based on the latest financial reports, ProQR Therapeutics BV (PRQR) has total liabilities worth $54.05 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PRQR financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of ProQR Therapeutics BV (2012–2025)
Total liabilities of ProQR Therapeutics BV from 2012 to 2025. This chart illustrates how ProQR Therapeutics BV's total liabilities have evolved over time, based on quarterly financial data. Explore ProQR Therapeutics BV long-term investment intensity to see how much of total assets are deployed in long-term investments.
ProQR Therapeutics BV Competitors by Total Liabilities
The table below lists competitors of ProQR Therapeutics BV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Newbury Street II Acquisition Corp Class A Ordinary Shares
NASDAQ:NTWO
|
USA | $6.16 Million |
|
Nextgreen Global Bhd
KLSE:7241
|
Malaysia | RM245.65 Million |
|
TTFB Co Ltd
TWO:2729
|
Taiwan | NT$4.12 Billion |
|
PT Multikarya Asia Pacific Ray
JK:MKAP
|
Indonesia | Rp169.19 Billion |
|
KOSKISEN OYJ EO 1
F:EZ8
|
Germany | €158.72 Million |
|
Wildcat Resources Ltd
AU:WC8
|
Australia | AU$3.34 Million |
|
NorAm Drilling AS
F:TM9
|
Germany | €20.14 Million |
|
Ndr Auto Components Limited
NSE:NDRAUTO
|
India | Rs1.99 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down ProQR Therapeutics BV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ProQR Therapeutics BV (PRQR) total assets.
Liquidity & Leverage Metrics
ProQR Therapeutics BV Total Liabilities Ratios Explained
ProQR Therapeutics BV total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.68 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ProQR Therapeutics BV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ProQR Therapeutics BV (2012–2025)
The table below shows the annual total liabilities of ProQR Therapeutics BV from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $74.44 Million | -9.46% |
| 2024-12-31 | $82.22 Million | -22.87% |
| 2023-12-31 | $106.59 Million | -4.55% |
| 2022-12-31 | $111.68 Million | +1.92% |
| 2021-12-31 | $109.57 Million | +112.29% |
| 2020-12-31 | $51.61 Million | +93.99% |
| 2019-12-31 | $26.61 Million | +51.63% |
| 2018-12-31 | $17.55 Million | +6.05% |
| 2017-12-31 | $16.54 Million | +26.43% |
| 2016-12-31 | $13.09 Million | +16.84% |
| 2015-12-31 | $11.20 Million | +58.41% |
| 2014-12-31 | $7.07 Million | +11.71% |
| 2013-12-31 | $6.33 Million | +1908.56% |
| 2012-12-31 | $315.10K | -- |
About ProQR Therapeutics BV
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic disea… Read more